Related Experiment Video
Updated: Oct 6, 2025

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
Published on: July 26, 2017
Bibliometric analysis of toll-like receptor agonists associated with cancer therapy
Wei Li1, Li Wan1, Shaojun Duan2
1Department of Pharmacy, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Background:
Toll-like receptors (TLRs), a family of innate pattern-recognition receptors, have been exploited as a target for antitumor strategy. An increasing number of TLR agonists, serving as immunotherapeutics or vaccine adjuvants, were developed. This study aimed at exploring the status and trend of current researches on TLR agonists through bibliometric analysis.
Methods:
Original publications on TLR agonists were collected from the Web of Science Core Collection. Data were analyzed in terms of publication outputs, journals, countries, institutions, authors, co-authorship, co-citation, research hotspots, and evolution trends through VOSviewer and CiteSpace.
Results:
A total of 1914 TLR agonists-related articles, published in 612 academic journals between 2000 and 2019, were enrolled in the study. The Journal of Immunology published the most publications, followed by PLoS One and Blood. The USA that is in possession of the largest number of articles and the most extensive cooperators was the most leading country in this field. University of Minnesota ranked the first in terms of paper totality, but its average citations ranking was lower than University of Pennsylvania. Gudkov AV was the most productive author, whose team reported a TLR5 agonist that had radioprotective activity in mouse and primate models in 2008. The paper of Akira Shizuo, professor of Osaka University, was widely cited by international peers. The research trend of TLR agonists has undergone 3 periods: mechanisms of TLR signalings in immunotherapy (2000-2010), discovery of TLR agonists (2011-2014), application, therapeutic evaluation, and drug design of TLR agonists (2015-2019).
Conclusion:
This study provides investigators a landscape of TLR agonists research from the perspective of bibliometrics.
Insights
This bibliometric analysis reveals key trends in Toll-like receptor (TLR) agonist research. The field evolved from understanding TLR signaling mechanisms to discovering and applying TLR agonists for immunotherapy and vaccine development.
Area of Science:
- Immunology
- Pharmacology
- Bibliometrics
Background:
- Toll-like receptors (TLRs) are innate immune system pattern-recognition receptors targeted for antitumor strategies.
- Numerous TLR agonists have been developed as immunotherapeutics and vaccine adjuvants.
- Bibliometric analysis provides insights into the research landscape of TLR agonists.
Purpose of the Study:
- To analyze the publication output, key journals, leading countries, institutions, and authors in TLR agonist research.
- To identify research hotspots and evolution trends in the field of TLR agonists.
- To provide a bibliometric overview of TLR agonist research from 2000 to 2019.
Main Methods:
- Collected 1914 articles on TLR agonists from the Web of Science Core Collection (2000-2019).
- Analyzed publication data using VOSviewer and CiteSpace software.
- Examined publication outputs, journals, countries, institutions, authors, co-authorship, co-citation, hotspots, and trends.
Main Results:
- The USA led in publications and international collaboration; The Journal of Immunology published the most articles.
- University of Minnesota and University of Pennsylvania were leading institutions; Gudkov AV and Akira Shizuo were highly productive/cited authors.
- Research trends shifted from TLR signaling mechanisms (2000-2010) to agonist discovery (2011-2014) and then to therapeutic applications (2015-2019).
Conclusions:
- Bibliometric analysis offers a comprehensive landscape of TLR agonist research.
- The study highlights the dynamic evolution of TLR agonist research, from basic mechanisms to clinical applications.
- This overview aids researchers in understanding the current status and future directions in the field.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
lncRNA - Long Non-coding RNAs
Tumor Immunotherapy

